Charles River Laboratories International, Inc. (CRL) closed at $337.95 on November 14, 2026, a decline of 0.84% over the prior 24 hours. The modest pullback came despite a broadly positive medium-term trend for the stock.
Over the past seven days, shares have added 0.21%, suggesting the recent session's dip did not meaningfully disrupt the stock's near-term stability. The more notable figure comes from the 30-day window, where CRL has risen 11.89%, pointing to a sustained period of buying interest.
The company's market capitalization stands at $16.33 billion, reflecting its position as a significant player in the contract research and preclinical services sector. The single-session decline appeared limited in scope relative to the broader gains accumulated over the past month.
With a 30-day advance of nearly 12% now on record, Friday's pullback represents a relatively minor fluctuation within what has been a strong stretch of performance for Charles River Laboratories shares.



